Generation of Defined Genomic Modifications Using CRISPR-CAS9 in Human Pluripotent Stem Cells
Summary
This protocol provides a method to facilitate the generation of defined heterozygous or homozygous nucleotide changes using CRISPR-CAS9 in human pluripotent stem cells.
Abstract
Human pluripotent stem cells offer a powerful system to study gene function and model specific mutations relevant to disease. The generation of precise heterozygous genetic modifications is challenging due to CRISPR-CAS9 mediated indel formation in the second allele. Here, we demonstrate a protocol to help overcome this difficulty by using two repair templates in which only one expresses the desired sequence change, while both templates contain silent mutations to prevent re-cutting and indel formation. This methodology is most advantageous for gene editing coding regions of DNA to generate isogenic control and mutant human stem cell lines for studying human disease and biology. In addition, optimization of transfection and screening methodologies have been performed to reduce labor and cost of a gene editing experiment. Overall, this protocol is widely applicable to many genome editing projects utilizing the human pluripotent stem cell model.
Introduction
Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are valuable tools for modeling human disease due to their capacity for renewal, while maintaining the ability to generate cell types of different lineages1,2,3,4. These models open the possibility to interrogate gene function, and understand how specific mutations and phenotypes are related to various diseases5,6. However, to understand how a specific alteration is linked to a particular phenotype, the use of a paired isogenic control and mutant cell lines is important to control for line to line variability7,8. Transcription activator-like effector nucleases (TALENs) and zinc finger nucleases have been used to generate insertion or deletion (indels) mutations in diverse genetic models, including primary cells; but these nucleases can be cumbersome to use and expensive9,10,11,12,13,14. The discovery of the clustered regularly interspaced short palindromic repeat (CRISPR)-CAS9 nuclease has revolutionized the field due to efficiency in indel formation in virtually any region of the genome, simplicity of use, and reduction in cost15,16,17,18,19.
A challenge in using the CRISPR-CAS9 based genome editing technology has been the generation or correction of specific mutations in one allele without creating an indel mutation in the second allele20. The major goal of this protocol is to overcome this challenge by using two single-stranded oligonucleotide (ssODN) repair templates to reduce indel formation in the second allele. Both ssODNs are designed to contain silent mutations to prevent re-cutting by the CAS9 nuclease, but only one contains the alteration of interest. This method increases the efficiency of generating a specific heterozygous genetic modification without inducing indel formation in the second allele. Using this protocol, gene editing experiments in six independent genomic locations demonstrate the precise introduction of the desired genomic change in one allele without indel formation in the second allele and occurs with an overall efficiency of ~10%. The described protocol has been adapted from Maguire et al.21.
Protocol
1. Design and construction of guide RNA (gRNA)
NOTE: Each gRNA is made up of two 60 base pair (bp) oligonucleotides that are annealed to generate a 100 bp double stranded (ds) oligonucleotide (Figure 1A-C). The timeline for gRNA design, generation, and testing cutting efficiency is approximately 2 weeks (Figure 2).
- Select the DNA region of interest to be genome edited and identify 3-4 23 bp sequences that fit the format, 5'-G(N19)NGG-3'. These sequences should be located within 20 bp of the region of interest.
NOTE: Targeting can be performed on the sense or anti-sense strand. - Evaluate the gRNA sequences for genomic redundancy and off-target probability using a resource such as CRISPOR (http://crispor.tefor.net).
- Incorporate the 20 bp target sequence (excluding the protospacer adjacent motif or PAM) into two 60-mer oligonucleotides as shown (sequences are 5' to 3' and red and green are reverse complements as shown in Figure 1C).
- Order the two 60 bp oligonucleotides from vendor of choice. Once the oligonucleotides are received, resuspend each to a final concentration of 100 µM in ddH2O. Make a working stock of 10 µM.
- Anneal the two oligonucleotides and generate a 100 bp dsDNA fragment using DNA polymerase (Table of Materials). Combine 5 µL of 10 µM forward oligonucleotide and 5 µL of 10 µM reverse oligonucleotide in a polymerase chain reaction (PCR) strip tube and incubate at 95 °C for 5 min. Cool the reaction for 10 min at room temperature (RT).
- Set up the PCR as described in Table 1. Perform PCR amplification in a thermal cycler using the parameters outlined in Table 2.
- Visualize the PCR products on a 1.5% (w/v) ethidium bromide (EtBr) agarose gel electrophoresed at 80-100 V for 40 min. Excise the 100 bp band (Figure 3A), visualized on an LED light box, from the gel using a razor blade and purify using a gel extraction kit (Table of Materials).
2. Design of PCR primers for screening
- Perform screening of the edited DNA using forward and reverse PCR primers that are specifically designed to amplify a 400-500 bp region of the gene of interest (Table 2). Use DNA isolated from any control iPSC line to confirm a clean amplicon when performing the screening PCR.
- Visualize PCR products on a 1.5% (w/v) gel following electrophoresis at 80-100 V for 1 h.
NOTE: Sequencing of edited clones is performed using a nested primer that is designed following confirmation of the screening primer set. Samples are sent to a commercial source for sequencing.
3. Preparation of gRNA_cloning vector plasmid
- To linearize the cloning vector, take a 1.5 mL centrifuge tube and add 1-5 µg of DNA of the gRNA_cloning vector along with 4 µL of the AflII restriction enzyme buffer and 1.5 µL of AflII restriction enzyme. Bring up the reaction to 24 µL of ddH2O. Mix the reaction by pipetting up and down. Incubate at 37 °C overnight (O/N).
- Electrophorese on a 1% agarose gel at 80-100 V for 1 h and excise bands (expected band size is ~3519 bp).
- Extract and purify as in step 1.6.
4. Assembly of gRNA vector
- Set up reactions and assemble DNA fragments using the assembly kit (Table of Materials) at 1:5 ratios of AflII digested gRNA cloning vector to 100 bp gel purified insert, as described in Table 3.
- Incubate the reaction at 50 °C for 15 min. Dilute the reaction 1:3 in ddH2O and use 3 µL for bacterial transformation, as per manufacturer’s instructions (Table of Materials). Plate cells on kanamycin LB/agar plates.
- Pick 3-5 colonies per gRNA. Inoculate each colony in 4 mL of LB and grow O/N at 37 °C in an orbital shaking incubator.
- Purify plasmid DNA using a miniprep plasmid isolation kit, and sequence each gRNA using the following primers to ensure successful cloning: Forward: GTACAAAAAAGCAGGCTTTAAAGG; Reverse: TGCCAACTTTGTACAAGAAAGCT.
5. Test gRNA cutting efficiency
- Plate hESCs on irradiated murine embryonic fibroblasts (MEFs) in a 6-well plate, as previously described21. When the cells reach 70-80% confluency, prepare the transfection master mix outlined in Table 4.
- Mix by pipetting and incubate at RT for 15 min. Add dropwise to the cells and incubate at 37 °C for 48 h (with a media change after 24 h).
- Harvest cells for sorting after 48 h.
- Remove MEFs enzymatically (Table of Materials) with a 3 min RT incubation.
- Rinse cells 1x with hESC medium (Table 5) and scrape into hESC medium + 10 µM Y-27632 dihydrochloride (Table of Materials).
- Pellet cells at 300 x g for 3 min and resuspend in 0.5 mL of hESC medium + 10 µM Y-27632 dihydrochloride.
- Filter into a 5 mL tube through a 35 µm cell-strainer cap.
- Using fluorescence activated cell sorting (FACS), gate on live cells and sort the green fluorescent protein (GFP) positive cells.
- Transfer a maximum of 1.5 x 104 sorted cells directly into a 10 cm2 dish coated with 1:3 basement membrane matrix (Table of Materials) and irradiated MEFs in hESC medium (Table 5) containing Y-27632 dihydrochloride.
- Change medium daily using the hESC medium (Table 5) without Y-27632 dihydrochloride and manually pick clones after 10-15 days, when colonies are ~1 mm in diameter.
- Using a P200 pipette and microscope, carefully scrape a single clone and draw cells into the pipette.
- Disperse the cells by gently pipetting 3-4x in a 96 well plate in the medium drawn up with the colony.
- Dispense into PCR strip tubes for screening and pellet the cells by centrifugation at 10,000 x g for 5 min. Pick 20 colonies per gRNA.
6. Clone screening
- Isolate DNA by incubating cell pellets in 20 µL of proteinase K buffer (Table 5) (1 h at 55 °C and 10 min at 95 °C) and vortex vigorously. Centrifuge at 10,000 x g for 5 min and collect the supernatant.
- Perform screening PCR (section 2) in a total volume of 20 µL using a master mix including primers designed to amplify the region of interest and 5 µL of the proteinase K digest. Use genomic DNA isolated from the cell line that was gene edited as a control.
- Evaluate size changes of PCR products following 1 h electrophoresis at 70-90 V on a 2.5% (w/v) agarose gel (Figure 3B,C). Any size difference is indicative of cleavage.
7. Precise genome editing in pluripotent stem cells using single strand oligo DNA (ssODNs)
- Design 100 bp ssODNs centered around the most efficient gRNA sequence determined to have the best cutting efficiency.
- Prevent re-cleavage of the recombined ODN by introducing silent mutations in the gRNA sequence. A single silent mutation in the PAM sequence is sufficient, but if not possible, 3-4 silent mutations will work.
NOTE: To facilitate screening of targeted clones, the introduction of a restriction site within ~20 bp of the gRNA sequence is ideal. - Design one ODN with the desired base change(s) to create the mutation of interest and one ODN without the base change(s).
NOTE: These changes should be no more than ~20 bp from the predicted CRISPR/CAS9 cut site, as recombination drops off considerably at greater distances. - Order the two ssODNs from vendor of choice and resuspend in water to make 1 µg/µL stocks. Store stocks at -20 °C.
8. Transfection setup
- To transfect the ssODN and the CRISPR-CAS9 plasmids, plate the target cell line in a 6-well dish on irradiated MEFs to reach 70-80% confluency after an O/N incubation.
- Set up the transfection reaction as described in Table 6. Mix the reaction by pipetting and incubate for 15 min at RT. Add the transfection reaction mixture dropwise to the cells.
- After 48 h, prepare the cells for cell sorting as described in section 5.3.
- Pick colonies ~10 days after plating single cells using a 200 μL pipette. Transfer 100 μL of cells to one well of a 24 or 48 well plate previously coated with gelatin and irradiated MEFs in hESC medium with Y-27632 dihydrochloride. Use the remaining 100 μL for DNA isolation as described in section 6.
9. Checking for mutations in single colonies
- To check for successful integration of the ssODN, take 5 µL of DNA isolated from each colony to perform PCR using the screening primers designed in section 2. Purify the PCR products (Table of Materials) and prepare the restriction enzyme digestion using the unique enzyme site created in the ssODN.
NOTE: This digestion also includes the restriction enzyme buffer and the manufacturer's recommended concentration of restriction enzyme in a volume of 40 µL. - Mix the reaction by pipetting and incubate at the manufacturer's recommended temperature for 1-3 h.
- Visualize the digested PCR products on a 1.5% (w/v) EtBr agarose gel electrophoresed at 80-100 V for 40 min. If successful integration of the ssODN has occurred, sequence specific mutations using a nested primer.
Representative Results
Generation of gRNAs and screening for indels
Each gRNA will be cloned into a plasmid vector and expressed using the U6 promoter. The AflII restriction enzyme is used to linearize the plasmid (addgene #41824) and is located after the U6 promoter. The 100 bp band generated after annealing the two 60 bp oligos is cloned into the gRNA expression vector using the DNA assembly. Once the gRNA plasmids are generated, they are transfected into hESCs or iPSCs along with a CRISPS-CAS9 GFP plasmid (addgene #44719). The GFP+ cells are sorted after 2 days to enrich for transfected cells and plated (see section 5). After 10-14 days, single cell derived colonies are picked and used to isolate DNA to screen for indel formation generated for each gRNA. A PCR amplification with primers spanning the gRNA site is used to visualize indel formation using a 2.5% (w/v) agarose gel with EtBr, electrophoresed at 70-90 V for 1 h.
Generation of 100 bp ssODN to introduce specific mutations
Two ssODN oligos are designed around the gRNA with the most efficient cutting. Each gRNA is 100 bp and contains silent mutations, preferably at the PAM sequence, to avoid re-cutting (Figure 4A). A silent mutation in the PAM sequence can generate a unique restriction site, which helps to screen for successful integration into one or two alleles (Figure 4B).
ssODN recombination outcomes
Using this protocol, the frequency of targeting events for six different genes using the two ssODN approach is shown in Figure 5. By examining genomic modification at the gRNA site in both alleles, different outcomes were expected including recombination of the wildtype (WT) ssODN, the mutant ssODN and indel formation. The clones in which only one allele had undergone recombination, the most common outcome was indel formation in the second allele (10-42%). The clones that had integration of the ssODNs in both alleles led to three different outcomes: 1) integration of the WT ssODN in both alleles (0-8%), 2) integration of the mutant ssODN in both alleles (0-25%), and 3) integration of both the WT and mutant ssODN WT (8-21%).
Figure 1: Overview of gRNA generation. (A) In the region of interest, design four gRNAs ending in GG that are not more than 20 bp apart. (B) Each gRNA of 23 bp has a PAM sequence of NGG at the 3' end. (C) The 60 bp primers are comprised of a 40 bp sequence complementary to the gRNA backbone plasmid and the 20 bp gRNA sequence without the PAM sequence. Please click here to view a larger version of this figure.
Figure 2: Protocol timeline for gRNA generation and clone screening. The timeline for gRNA generation and screening clones is shown. Designing and cloning gRNA expression plasmids takes approximately one week. Approximately 48 hours after transfection into human PSCs, GFP+ cells are sorted and plated at limiting dilution. Colonies should be visible between 7-10 days and at approximately day 20, clones can be picked for screening, expansion, and sequence confirmation. Please click here to view a larger version of this figure.
Figure 3: gRNA test for cutting efficiency. (A) For gRNA construction, a 100 bp band is excised from a 1.5% agarose gel. (B) Following cell transfection, validation of gRNA cutting is visualized using a 2.5% agarose gel. A 180 bp PCR product is used to check for indel formation in which an uncut control and different clones are analyzed for band shifts indicative of indel formation. (C) Different gRNAs may have different cutting efficiencies. Please click here to view a larger version of this figure.
Figure 4: Generation and screening of mutations using two ssODNs. (A) To avoid CRISPR-CAS9 re-cutting of the edited alleles, the PAM sequence can be modified using a G to A silent mutation. This modification adds a unique EcoRI restriction site that can be used for screening. In addition to this silent mutation, the mutant ssODN contains the desired base change. (B) Screening for oligonucleotide recombination using EcoRI restriction enzyme digestion can result in three possible outcomes: no cutting represented by a WT band at ~650 bp, recombination in one allele represented by an uncut band of 650 bp and two smaller bands or insertion into both alleles represented by only smaller bands. Please click here to view a larger version of this figure.
Figure 5: ssODN integration efficiency and outcomes. Integration efficiency and outcomes of the two ssODN approach were determined by analyzing six different genes. If only one ssODN integrated, indel formation was usually detected in the other allele. If two ssODNs integrated, three possible outcomes were detected, as shown. Please click here to view a larger version of this figure.
| Reagent | Volume (μL) |
| dNTPs (10 mM) | 0.4 |
| Taq polymerase | 0.2 |
| PCR buffer | 4.0 |
| Annealed oligos (10 μM) | 10.0 |
| ddH2O | 5.4 |
Table 1: gRNA cloning PCR conditions.
| PCR program | |
| Step 1 | 98 °C for 30 s |
| Step 2 | 98 °C for 10 s |
| Step 3 | 55 °C for 20 s |
| Step 4 | 72 °C for 30 s |
| Step 5 | Repeat steps 2−4 for 30 cycles |
| Step 6 | 72 °C for 5 min |
| Step 7 | Hold at 4 °C |
Table 2: PCR cycling parameters.
| Reagent | Volume (μL) |
| linearized gRNA vector using AflII (i.e., 50 ng/μL) | 1.0 |
| 100 bp DNA (i.e., 250 ng/μL) | 1.0 |
| Master mix 2x | 10.0 |
| ddH2O | q.s. to 20 |
Table 3: gRNA assembly reaction conditions.
| Reagent | Amount |
| DMEM/F12 | 50.0 μL |
| pCas9_GFP vector (addgene plasmid 44719) | 0.5 μg |
| gRNA plasmid | 0.5 μg |
| lipid transfection reagent | 3.0 μL |
Table 4: Cell transfection master mixture.
| hESC medium | |
| Reagent | Final concentration |
| DMEM/F12 | |
| Knockout serum replacement (KDR) | 15% (v/v) |
| Nonessential amino acids | 100 µM |
| Sodium pyruvate | 1 mM |
| Glutamine | 2 mM |
| β-mercaptoethanol | 0.1 mM |
| bFGF human (basic fibroblast growth factor) | 10 ng/mL |
| 10x Proteinase K buffer | |
| Tris.HCl pH:7.4 | 50 mM |
| Ammonium sulfate pH: 9.3 | 15 mM |
| MgCl2 | 2.5 mM |
| Tween 20 | 0.1% (v/v) |
| Proteinase K | 100 µg/mL |
Table 5: Cell culture medium and proteinase K digestion buffer.
| Reagent | Amount |
| DMEM/F12 | 50.0 μL |
| pCas9_GFP vector (addgene plasmid 44719) | 0.5 μg |
| gRNA plasmid | 0.5 μg |
| ssODN (0.5 μg of each ssODN) | 1.0 μg |
| lipid transfection reagent | 3.0 μL |
Table 6: ssODN cell transfection master mixture.
Discussion
In this protocol, the use of CRISPR-CAS9 along with two ssODN repair templates to generate specific heterozygous or homozygous genome changes is demonstrated in human pluripotent stem cells. This method resulted in the successful generation of isogenic cell lines expressing heterozygous genomic changes with an efficiency close to 10%. This protocol has been optimized for both human ESCs and iPSCs grown on irradiated MEFs which support cell growth and survival after culturing cells at low density after cell sorting. Cell death can be minimized by maintaining cells with 10 ng/mL bFGF and Y-27632 dihydrochloride. It is possible that this protocol may be adapted to feeder free culture systems, but further optimization may be necessary.
Transfection efficiency can be variable from cell line to cell line, but the use of 3 µg of DNA and 3 µL of a lipid transfection reagent generally gave the best results of between 0.5-2% transfection efficiency. However, if transfection efficiency is lower, optimization of the amount of DNA and lipid reagent can be performed. Other transfection reagents can also be tested by the investigator.
The efficiency of indel generation will vary with different gRNAs and can be influenced by genomic location. Within the vast majority of cases, if four gRNAs are designed, at least one and many times 2 to 3, will work efficiently. Additionally, prior to testing gRNAs, optimization of the PCR strategy to visualize indels with a clean single band DNA product is important. For screening ssODN based genome editing, it is best to add a restriction enzyme site when introducing a silent mutation(s), but if not possible, deletion of a restriction enzyme site can be used as well. In addition, homology directed repair requires actively cycling cells so the cell density of cultures prior to transfection is critical to enhance the frequency of clones repaired using the introduced ssODN template.
Some of the limitations of this protocol are related to the position in the genome that will be edited. When coding regions are modified, ssODN carrying silent mutations prevent the Cas9 from re-cutting the edited site and the silent mutations do not alter the protein product. However, editing in regulatory or non-coding regions using this methodology becomes more difficult as silent mutations are not possible. If the base to be edited is part of a PAM sequence, this can be done successfully but only homozygous changes can be generated efficiently.
The protocol described here is useful to generate or correct heterozygous coding mutations without the addition of unintended indels in the second allele. This protocol will facilitate the use of human PSCs to study a wide range of topics from developmental biology to modeling of genetic diseases. The use of isogenic lines is critical to define functions of a given coding mutation without confounding effects due to differing genetic backgrounds.
Divulgaciones
The authors have nothing to disclose.
Acknowledgements
This research was supported by funding from the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health through grants U01HL099656 (P.G. and D.L.F.) and U01HL134696 (P.G. and D.L.F.).
Materials
| 5-ml polystyrene round-bottom tube with cell-strainer cap | Corning | 352235 | |
| 6-well polystyrene tissue culture dishes | Corning | 353046 | |
| AflII restriction endonuclease | New England Biolabs | R0520 | |
| Agarose | VWR | N605 | |
| DMEM/F12 medium | ThermoFisher | 11320033 | |
| dNTPs | Roche | 11969064001 | |
| Fluorescence-activated cell sorter (FACS) apparatus | |||
| Gel extraction kit | Macherey-Nagel | 740609 | |
| Gibson Assembly Kit | New England Biolabs | E2611 | |
| gRNA_Cloning Vector | Addgene | 41824 | |
| LB agar plates containing 50 μg/ml kanamycin | |||
| Lipofectamine Stem Reagent | ThermoFisher | (STEM00001) | |
| Matrigel Growth Factor Reduced (GFR) | Corning | 354230 | |
| Murine embryonic fibroblasts (MEFs) | |||
| Nucleospin Gel Extraction and PCR Clean-up Kit | Macherey-Nagel | 740609 | |
| Orbital shaking incubator | |||
| pCas9_GFP vector | Addgene | 44719 | |
| PCR strip tubes | USA Scientific | 1402-2900 | |
| Phusion High Fidelity DNA Polymerase and 5× Phusion buffer | New England Biolabs | M0530 | |
| PurelinkTM Quick Plasmid Miniprep Kit | Invitrogen | K210011 | |
| Proteinase K | Qiagen | Qiagen 19133 | |
| StellarTM electrocompetent Escherichia coli cells | Takara | 636763 | |
| SOC medium | New England Biolabs | B9020S | |
| TrypLE Express Enzyme | ThermoFisher | 12605036 | |
| Y-27632 dihydrochloride/ROCK inhibitor (ROCKi) | Tocris | 1254 |
Referencias
- Srivastava, D., Dewitt, N. Review In Vivo Cellular Reprogramming: The Next Generation. Cell. 166 (6), 1386-1396 (2016).
- Clevers, H. Review Modeling Development and Disease with Organoids. Cell. 165 (7), 1586-1597 (2016).
- Murry, C. E., Keller, G. Differentiation of Embryonic Stem Cells to Relevant Populations: Lessons from Embryonic Development. Cell. 132 (4), 661-680 (2008).
- Liu, C., Oikonomopoulos, A., Sayed, N., Wu, J. C. Modeling human diseases with induced pluripotent stem cells: from 2D to 3D and beyond. Development. 145 (5), 1-6 (2018).
- Avior, Y., Sagi, I., Benvenisty, N. Pluripotent stem cells in disease modelling and drug discovery. Nature Reviews Molecular Cell Biology. 17 (3), 170-182 (2016).
- Tiyaboonchai, A., et al. GATA6 Plays an Important Role in the Induction of Human Definitive Endoderm, Development of the Pancreas, and Functionality of Pancreatic β Cells. Stem Cell Reports. 8 (3), 589-604 (2017).
- Guo, M., et al. Using hESCs to Probe the Interaction of the Diabetes-Associated Genes CDKAL1 and MT1E. Cell Reports. 19 (8), 1512-1521 (2017).
- Zeng, H., et al. An Isogenic Human ESC Platform for Functional Evaluation of Genome-wide-Association-Study-Identified Diabetes Genes and Drug Discovery. Cell Stem Cell. 19 (3), 326-340 (2016).
- Wang, Y., et al. Genome editing of human embryonic stem cells and induced pluripotent stem cells with zinc finger nucleases for cellular imaging. Circulation Research. 111, 1494-1503 (2012).
- Xue, H., Wu, J., Li, S., Rao, M. S., Liu, Y. Genetic Modification in Human Pluripotent Stem Cells by Homologous Recombination and CRISPR/Cas9 System. Methods in Molecular Biology. 1307, 173-190 (2014).
- Huang, X., et al. Production of gene-corrected adult beta globin protein in human erythrocytes differentiated from patient iPSCs after genome editing of the sickle point mutation. Stem Cells. 33 (5), 1470-1479 (2015).
- Wang, X., et al. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nature Biotechnology. 33 (2), 175-178 (2015).
- Sim, X., Cardenas-Diaz, F. L., French, D. L., Gadue, P. A Doxycycline-Inducible System for Genetic Correction of iPSC Disease Models. Methods in Molecular Biology. 1353, 13-23 (2015).
- Hockemeyer, D., Jaenisch, R. Review Induced Pluripotent Stem Cells Meet Genome Editing. Stem Cell. 18 (5), 573-586 (2016).
- Byrne, S. M., Mali, P., Church, G. M. Genome editing in human stem cells. Methods in Enzymology. 546, 119-138 (2014).
- Zhu, Z., González, F., Huangfu, D. The iCRISPR platform for rapid genome editing in human pluripotent stem cells. Methods in Enzymology. 546, 215-250 (2014).
- Hou, Z., et al. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proceedings of the National Academy of Sciences of the United States of America. 110 (39), 15644-15649 (2013).
- Cong, L., Zhang, F. Genome engineering using CRISPR-Cas9 system. Methods in Molecular Biology. 1239, 197-217 (2015).
- Mali, P., Esvelt, K. M., Church, G. M. Cas9 as a versatile tool for engineering biology. Nature Methods. 10 (10), 957-963 (2013).
- Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L., Corn, J. E. Enhancing homology directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nature Biotechnology. 34 (3), 339-344 (2016).
- Maguire, J. A., Cardenas-Diaz, F. L., Gadue, P., French, D. L. Highly efficient crispr cas9-mediated genome editing in human pluripotent stem cells. Current Protocols in Stem Cell Biology. 48 (1), 64 (2019).
